569 related articles for article (PubMed ID: 33754044)
21. A gene-based survival score for lung adenocarcinoma by multiple transcriptional datasets analysis.
Xiong Y; Lei J; Zhao J; Lu Q; Feng Y; Qiao T; Xin S; Han Y; Jiang T
BMC Cancer; 2020 Oct; 20(1):1046. PubMed ID: 33129284
[TBL] [Abstract][Full Text] [Related]
22.
Liu L; Wang C; Li S; Qu Y; Xue P; Ma Z; Zhang X; Bai H; Wang J
Front Immunol; 2021; 12():677169. PubMed ID: 34354701
[TBL] [Abstract][Full Text] [Related]
23. A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma.
Jones GD; Brandt WS; Shen R; Sanchez-Vega F; Tan KS; Martin A; Zhou J; Berger M; Solit DB; Schultz N; Rizvi H; Liu Y; Adamski A; Chaft JE; Riely GJ; Rocco G; Bott MJ; Molena D; Ladanyi M; Travis WD; Rekhtman N; Park BJ; Adusumilli PS; Lyden D; Imielinski M; Mayo MW; Li BT; Jones DR
JAMA Surg; 2021 Feb; 156(2):e205601. PubMed ID: 33355651
[TBL] [Abstract][Full Text] [Related]
24. Systematic construction and validation of an immune prognostic model for lung adenocarcinoma.
Luo C; Lei M; Zhang Y; Zhang Q; Li L; Lian J; Liu S; Wang L; Pi G; Zhang Y
J Cell Mol Med; 2020 Jan; 24(2):1233-1244. PubMed ID: 31779055
[TBL] [Abstract][Full Text] [Related]
25. Digital Inference of Immune Microenvironment Reveals Low-Risk Subtype of Early Lung Adenocarcinoma.
Kurbatov V; Balayev A; Saffarzadeh A; Heller DR; Boffa DJ; Blasberg JD; Lu J; Khan SA
Ann Thorac Surg; 2020 Feb; 109(2):343-349. PubMed ID: 31568747
[TBL] [Abstract][Full Text] [Related]
26. Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma.
Shukla S; Evans JR; Malik R; Feng FY; Dhanasekaran SM; Cao X; Chen G; Beer DG; Jiang H; Chinnaiyan AM
J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27707839
[TBL] [Abstract][Full Text] [Related]
27. Screening of Methylation Gene Sites as Prognostic Signature in Lung Adenocarcinoma.
Dong M; Yang Z; Li X; Zhang Z; Yin A
Yonsei Med J; 2020 Dec; 61(12):1013-1023. PubMed ID: 33251775
[TBL] [Abstract][Full Text] [Related]
28. Development and validation of a hypoxia-related gene signature to predict overall survival in early-stage lung adenocarcinoma patients.
Sun J; Zhao T; Zhao D; Qi X; Bao X; Shi R; Su C
Ther Adv Med Oncol; 2020; 12():1758835920937904. PubMed ID: 32655701
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinoma.
Zhang C; Zhang Z; Zhang G; Zhang Z; Luo Y; Wang F; Wang S; Che Y; Zeng Q; Sun N; He J
Cancer Lett; 2020 Jun; 479():31-41. PubMed ID: 32201203
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive analysis of microenvironment-related genes in lung adenocarcinoma.
Tao Y; Li Y; Liang B
Future Oncol; 2020 Aug; 16(24):1825-1837. PubMed ID: 32501723
[No Abstract] [Full Text] [Related]
31. Identification and Validation of a Proliferation-Associated Score Model Predicting Survival in Lung Adenocarcinomas.
Bian Y; Sui Q; Bi G; Zheng Y; Zhao M; Yao G; Xue L; Zhang Y; Fan H
Dis Markers; 2021; 2021():3219594. PubMed ID: 34721732
[TBL] [Abstract][Full Text] [Related]
32. A tumor microenvironment-related mRNA-ncRNA signature for prediction early relapse and chemotherapeutic sensitivity in early-stage lung adenocarcinoma.
Gao Z; Han H; Zhao Y; Yuan H; Zheng S; Zhang Y; Chen H
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3195-3209. PubMed ID: 34291356
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive molecular analyses of a TNF family-based signature with regard to prognosis, immune features, and biomarkers for immunotherapy in lung adenocarcinoma.
Zhang C; Zhang G; Sun N; Zhang Z; Zhang Z; Luo Y; Che Y; Xue Q; He J
EBioMedicine; 2020 Sep; 59():102959. PubMed ID: 32853987
[TBL] [Abstract][Full Text] [Related]
34. Identification of a novel ADCC-related gene signature for predicting the prognosis and therapy response in lung adenocarcinoma.
Zhang L; Zhang X; Guan M; Zeng J; Yu F; Lai F
Inflamm Res; 2024 May; 73(5):841-866. PubMed ID: 38507067
[TBL] [Abstract][Full Text] [Related]
35. Identification of theranostic factors for patients developing metastasis after surgery for early-stage lung adenocarcinoma.
Cheng WC; Chang CY; Lo CC; Hsieh CY; Kuo TT; Tseng GC; Wong SC; Chiang SF; Huang KC; Lai LC; Lu TP; Chao KSC; Sher YP
Theranostics; 2021; 11(8):3661-3675. PubMed ID: 33664854
[No Abstract] [Full Text] [Related]
36. Unique metastasis-associated lncRNA signature optimizes prediction of tumor relapse in lung adenocarcinoma.
Zhang X; Han J; Du L; Li X; Hao J; Wang L; Zheng G; Duan W; Xie Y; Zhao Y; Zhang X; Zou M; Wang C
Thorac Cancer; 2020 Mar; 11(3):728-737. PubMed ID: 31994347
[TBL] [Abstract][Full Text] [Related]
37. Exploration of predictive and prognostic alternative splicing signatures in lung adenocarcinoma using machine learning methods.
Cai Q; He B; Zhang P; Zhao Z; Peng X; Zhang Y; Xie H; Wang X
J Transl Med; 2020 Dec; 18(1):463. PubMed ID: 33287830
[TBL] [Abstract][Full Text] [Related]
38. Elevated FAM83A expression predicts poorer clincal outcome in lung adenocarcinoma.
Zhang J; Sun G; Mei X
Cancer Biomark; 2019; 26(3):367-373. PubMed ID: 31594212
[TBL] [Abstract][Full Text] [Related]
39. Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinoma.
Song Q; Shang J; Yang Z; Zhang L; Zhang C; Chen J; Wu X
J Transl Med; 2019 Mar; 17(1):70. PubMed ID: 30832680
[TBL] [Abstract][Full Text] [Related]
40. Construction and experimental validation of an acetylation-related gene signature to evaluate the recurrence and immunotherapeutic response in early-stage lung adenocarcinoma.
Wang H; Lu X; Chen J
BMC Med Genomics; 2022 Dec; 15(1):254. PubMed ID: 36503492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
